Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

141. Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. (PubMed)

Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Complications of chronic kidney disease (CKD) include weak bones and increased fracture risk.To review the benefits and harms of osteoporosis medications (bisphosphonates, teriparatide, raloxifene, and denosumab) compared with placebo, usual care, or active control in terms of bone mineral density (BMD), fractures, and safety in patients with CKD.PubMed and the Cochrane (...) ).There were 13 trials (n = 9850) that included kidney transplant recipients (6 trials), patients who had stage 3 to 5 CKD or were receiving dialysis (3 trials), or postmenopausal women with CKD (4 trials). Evidence showed that bisphosphonates may slow loss of BMD among transplant recipients (moderate SOE), but their effects on fractures and safety in transplant recipients and others with CKD are unclear. Raloxifene may prevent vertebral fractures but may not improve BMD (low SOE). Effects of teriparatide

2017 Annals of Internal Medicine

142. Etelcalcetide (Parsabiv) - To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis

Etelcalcetide (Parsabiv) - To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis Parsabiv (etelcalcetide) Injection U.S. Department of Health and Human Services Search FDA Submit search Parsabiv (etelcalcetide) Injection Parsabiv Company: Amgen, Inc. Application No.: 208325 Approval Date: 02/07/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2017 FDA - Drug Approval Package

143. Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease (PubMed)

Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease Coronary artery calcification (CAC) is highly prevalent in dialysis-naive patients with chronic kidney disease (CKD). However, there are sparse data on the association of CAC with subsequent risk of cardiovascular disease and all-cause mortality in this population.To study the prospective association of CAC with risk of cardiovascular disease and all-cause mortality among (...) dialysis-naive patients with CKD.The prospective Chronic Renal Insufficiency Cohort study recruited adults with an estimated glomerular filtration rate of 20 to 70 mL/min/1.73 m2 from 7 clinical centers in the United States. There were 1541 participants without cardiovascular disease at baseline who had CAC scores.Coronary artery calcification was assessed using electron-beam or multidetector computed tomography.Incidence of cardiovascular disease (including myocardial infarction, heart failure

Full Text available with Trip Pro

2017 JAMA cardiology

144. Low Urinary Creatinine Excretion Is Associated With Self-Reported Frailty in Patients With Advanced Chronic Kidney Disease (PubMed)

Low Urinary Creatinine Excretion Is Associated With Self-Reported Frailty in Patients With Advanced Chronic Kidney Disease Frailty and muscle wasting, a component of frailty, are common in advanced stage chronic kidney disease (CKD). Whether frailty is associated with low urinary creatinine excretion (UCrE) as a measure of muscle mass in this population is unknown. Furthermore, reference values of UCrE are lacking. We first defined low UCrE and studied correlates of low UCrE, and subsequently (...) of comorbidities. The frailty-associated variables hemoglobin and albumin were inversely associated with low UCrE, and parathyroid hormone was positively associated with low UCrE.Lower kidney function is a strong correlate of low UCrE and self-reported frailty, and the individual frailty components are associated with low UCrE as well, independent of comorbidities.

Full Text available with Trip Pro

2017 Kidney international reports

145. Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease (PubMed)

Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease Mortality among the patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) remains high because of the very high incidence of cardiovascular disease (CVD) such as coronary artery disease, cardiac hypertrophy, and heart failure. Identifying CVD in patients with CKD/ESRD remains a significant hurdle and the early diagnosis and therapy for CVD is crucial

Full Text available with Trip Pro

2017 Frontiers in cardiovascular medicine

146. Clinical relevancy and determinants of potential drug–drug interactions in chronic kidney disease patients: results from a retrospective analysis (PubMed)

Clinical relevancy and determinants of potential drug–drug interactions in chronic kidney disease patients: results from a retrospective analysis Chronic kidney disease (CKD) alters the pharmacokinetic and pharmacodynamic responses of various renally excreted drugs and increases the risk of drug-related problems, such as drug-drug interactions.To assess the pattern, determinants, and clinical relevancy of potential drug-drug interactions (pDDIs) in CKD patients.This study retrospectively

Full Text available with Trip Pro

2017 Integrated pharmacy research & practice

147. Is chronic kidney disease an adverse factor in lung cancer clinical outcome? A propensity score matching study (PubMed)

Is chronic kidney disease an adverse factor in lung cancer clinical outcome? A propensity score matching study Comorbidity has a great impact on lung cancer survival. Renal function status may affect treatment decisions and drug toxicity. The survival outcome in lung cancer patients with coexisting chronic kidney disease (CKD) has not been fully evaluated. We hypothesized that CKD is an independent risk factor for mortality in patients with lung cancer.A retrospective, propensity-matched study

Full Text available with Trip Pro

2017 Thoracic cancer

148. Iron (III) isomaltoside 1000 (Diafer) - For the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis

Iron (III) isomaltoside 1000 (Diafer) - For the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis 1 Published 13 February 2017 Re-submission iron III isomaltoside 1000 (contains 50mg iron per mL) (Diafer ® ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited 13 January 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use (...) in Scotland. The advice is summarised as follows: ADVICE: following a resubmission iron III isomaltoside 1000 5% (Diafer ® ) is accepted for use within NHS Scotland. Indication under review: For the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used. Iron III isomaltoside 1000 at a higher (10%) concentration has been shown to be non-inferior to another intravenous iron product in maintaining haemoglobin

2017 Scottish Medicines Consortium

149. Associations of Protein−Energy Wasting Syndrome Criteria With Body Composition and Mortality in the General and Moderate Chronic Kidney Disease Populations in the United States (PubMed)

Associations of Protein−Energy Wasting Syndrome Criteria With Body Composition and Mortality in the General and Moderate Chronic Kidney Disease Populations in the United States It is unknown whether the criteria used to define Protein-energy wasting (PEW) syndrome in dialysis patients reflect protein or energy wasting in the general and moderate CKD populations.In 11,834 participants in the 1999-2004 National Health and Nutrition Examination Survey, individual PEW syndrome criteria

Full Text available with Trip Pro

2017 Kidney international reports

150. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. (PubMed)

Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Recent changes to the U.S. Food and Drug Administration boxed warning for metformin will increase its use in persons with historical contraindications or precautions. Prescribers must understand the clinical outcomes of metformin use in these populations.To synthesize data addressing outcomes of metformin use in populations with type 2 diabetes (...) and moderate to severe chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease (CLD) with hepatic impairment.MEDLINE (via PubMed) from January 1994 to September 2016, and Cochrane Library, EMBASE, and International Pharmaceutical Abstracts from January 1994 to November 2015.English-language studies that: 1) examined adults with type 2 diabetes and CKD (with estimated glomerular filtration rate less than 60 mL/min/1.73 m2), CHF, or CLD with hepatic impairment; 2) compared

Full Text available with Trip Pro

2017 Annals of Internal Medicine

151. Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Indranil Dasgupta DM FRCP , Debasish Banerjee MD FRCP , Tahseen A Chowdhury MD FRCP , Parijat De MD FRCP , Mona Wahba MA FRCP , Stephen Bain MD FRCP , Andrew Frankel MD FRCP , Damian Fogarty MD FRCP , Ana Pokrajac (...) blockade in patients with type 2 diabetes, nephropathy and/or early chronic kidney disease (stages 1–3) 13 Recommendations 14 Audit standards 14 Areas that require further research 15 Introduction 15 The renin-angiotensin-aldosterone system 16 Hypertension in patients with type 2 diabetes 16 The role of home and ambulatory blood pressure measurement 16 Lifestyle modification and impact on blood pressure 17 Blood pressure lowering agents 18 RAAS blockade in patients with type 2 diabetes without

2017 Association of British Clinical Diabetologists

152. Association of British Clinical Diabetologists - Renal Association (ABCD-RA) Clinical Practice Guidelines for Management of Lipids in Adults with Diabetes Mellitus and Nephropathy and/or Chronic Kidney Disease

Association of British Clinical Diabetologists - Renal Association (ABCD-RA) Clinical Practice Guidelines for Management of Lipids in Adults with Diabetes Mellitus and Nephropathy and/or Chronic Kidney Disease ABCD-RA Clinical Practice Guidelines – Lipid management in DN &/or DM CKD. Online June 2017 © ABCD-RA 2017 1 CONTENTS Introduction ……………………………………. 2 Rationale for guidelines 22-24 ………… 14 Methodology…………………………………… 2 Rationale for guidelines 25-28 ……….. 15 Why do we need these guidelines (...) : +44 (0) 141 201 1100 E-mail: Patrick.mark@glasgow.ac.uk 2 Dr Peter Winocour East and North Herts Institute of Diabetes and Endocrinology (ENHIDE), Queen Elizabeth II Hospital, Welwyn Garden City, AL7 4HQ, UK Tel +44 (0) 1438 288324 E-mail: peter.winocour@nhs.net Address for correspondence & Association of British Clinical Diabetologists - Renal Association (ABCD-RA) Clinical Practice Guidelines for Management of Lipids in Adults with Diabetes Mellitus and Nephropathy and/or Chronic Kidney Disease

2017 Association of British Clinical Diabetologists

155. Hypertension management and use of antihypertensive medication in patients with chronic kidney disease

Hypertension management and use of antihypertensive medication in patients with chronic kidney disease

2017 DynaMed Plus